Entity
Description
  • Value proposition

    Combining human and machine intelligence to discover the next generation of therapeutic antibodies.

    LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVATM, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVATM is both modality and format-agnostic, LabGenius' internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The company's novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles.

    Medical, Health, and DNA Libraries

  • LabGenius Therapeutics | ML-driven Antibody Discovery

    Combining human and machine intelligence to discover the next generation of therapeutic antibodies.

  • https://labgeniustx.com/
Catalyst interactions
Catalyst TypeTweets Articles
Illumina For Startups
Illumina For Startups
Startup accelerator & VC, Biotechnology, Biotechnology Research
Illumina For Startups
Startup accelerator & VC, Biotechnology, Biotechnology Research
Other

25 Sep 2019


Google
Google
IT services, Software Development
Google
IT services, Software Development
Not capitalistic
Not partnership
Event

7 Jun 2018


CogX Festival
CogX Festival
Software Development
CogX Festival
Software Development
Not capitalistic
Not partnership
Event

8 Sep 2020

1 Oct 2023



Slush
Slush
Non-profit Organizations
Slush
Non-profit Organizations
Not capitalistic
Not partnership
Event

1 Dec 2017


Sanofi
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Not capitalistic
Partnership
Not event

15 Jul 2021

30 May 2024



Sifted
Sifted
Newspaper Publishing
Sifted
Newspaper Publishing
Not capitalistic
Not partnership
Event

16 Aug 2022

31 Aug 2023



Social network dynamics
Similar entities
BETA
Loading...
Loading...